THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Andy Liu, General ManagerNovotech provides clinical development services across all clinical trial phases and therapeutic areas. The company’s laboratory solutions span small and large molecule clinical sample analysis, biostorage, biologistics, and kit supply.
“We have a group of dedicated employees with a wide range of capabilities—from method development to data analysis-for customers from a clinical and registration perspective,” says Andy Liu, General Manager, China at Novotech. “As a global lab CRO, we have been operating according to the “one lab” standard, which is more conducive to test consistency and repeatability.”
Liu has extensive operational experience in the Asian CRO market. Prior to joining Novotech Health Holdings, he was the General Manager of Covance Central Laboratory (Asia Pacific), managing a multi-functional team of approximately 500 employees across multiple regions. This experience allows him to instill a global perspective into every Novotech project.
As a global company, Novotech is a great place to build a career. They are very focused on providing a motivating work environment with an inclusive culture, flexible workplace, and very high levels of transparency. All these factors have earned Novotech the trust of a large number of customers.
What propels Novotech forward even more is the company’s global perspective on the progress of drug development in different markets. They regularly work with clinical CRO colleagues, customers, and other personnel and researchers from different verticals to design effective solutions.
We have a group of dedicated employees with a wide range of capabilities—from method development to data analysis-for customers from a clinical and registration perspective
“As a clinical CRO company with full-service capability, we are focused on global biotech as well as global MRCT strategies for China mainland and abroad customers,” states Liu.
With a comprehensive clinical development services portfolio, Novotech will continue to invest and develop its lab capabilities across the region to serve global clients in the future.
Company
Novotech
Management
Andy Liu, General Manager
Description
Since establishing its first bioanalytical laboratory in Taiwan in 1997, Novotech has been at the forefront of assisting customers in every stage of their molecule development. The company has acquired three additional bioanalytical laboratories, in Xuzhou, Jiangsu Province, Shanghai, in China and Seoul, South Korea.
Novotech’s Vice President, Clinical Services Dr. Yooni Kim accepted the award at the 7th Cell & Gene Therapy World Asia conference last week in Singapore.
Novotech is also the recipient of the Best CRO for Cell & Gene Therapy2022 award.
Accepting the award, Dr. Kim thanked the organizers IMAPAC and stated “Novotech is proud to be recognised as an exceptional cell & gene therapy (CGT) CRO leader that facilitates rapid advancement in these new therapies.”
“One of the biggest challenges in CGT trials is managing regulatory approvals, especially for multi-country studies. This is where Novotech excels. With our considerable experience in the Asia Pacific since 1997, and in recent years in the US and Europe, we navigate the complexities of regulatory processes, ensuring seamless progress for our clients,” she remarked.
Dr. Kim also indicated the success of CGT trials also hinges on patient acceptance and understanding cultural nuances. “This means that a patient centric approach in carer engagement is vital for success. Novotech is committed to fostering this engagement throughout the entire clinical trial process.”
She remarked “according to our latest CGT clinical trial landscape report the global CGT market is projected to hit $93.78 billion by 2030 and FDA approvals for gene therapy in H2 2022 surpassed the combined total for the previous five years.”
Download Recent CGT Report here
“Asia Pacific is playing a significant role in the global CGT trials growth with an increase in percentage share from 41% in 2018 to 48% in 2022, demonstrating the region’s commitment to cutting-edge medical research. North America and Europe together had 54% in 2018 but fell to 47% in 2022,” she commented.
Dr. Kim noted mainland China and the United States, each with over 600 trials, were the leading locations in CGT trials, while over 450 CGT trials were initiated in European countries.
“From 2018-2022 the APAC region’s single country CGT trials share was 90%, North America was 69% and Europe was 35%.”
According to a recent report, China played a significant role in the APAC region, representing approximately 75% of the market share. Japan, South Korea, Taiwan, and Australia also made substantial contributions, accounting for 9%, 8%, 3%, and 2%, respectively. Other locations within the APAC region, such as India, Singapore, Malaysia, Hong Kong, New Zealand, and Thailand, collectively contributed 3% to the share of single-country CGT trials.
Novotech boasts a workforce of over 3,000 employees spread across 25 different geographical areas, with 34 office locations in places like Greater China, South Korea, Australia, New Zealand, the US, and Europe. The company offers a comprehensive range of services, spanning from early to late-phase clinical trials, and has a strong presence in the Asia Pacific region, known for its exceptional track record in delivering high-quality expedited clinical trials.
Novotech has earned recognition for its outstanding contributions to the industry, receiving prestigious awards such as the CRO Leadership Award 2023 and the Best CRO for Cell & Gene Therapy awards in 2022 and 2023. Furthermore, the company was honored with the Asia-Pacific Contract Research Organization Company of the Year Award. Its commitment to collaboration is evident through the 50 Leading Site Partnership agreements it has entered into over the past three years.